Evaluation of the Safety and Effectiveness of Pringle Method Combined With IVC Flow Limiting and Blocking Method in Laparoscopic Hepatectomy Based on Non-restrictive Fluid Therapy Strategy

Launched by SUN YAT-SEN MEMORIAL HOSPITAL OF SUN YAT-SEN UNIVERSITY · Sep 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to a type of surgery called laparoscopic hepatectomy, which is performed to remove tumors from the liver. The researchers want to see how safe and effective this new method is compared to a traditional approach. They will be looking at various factors during and after the surgery, such as how much blood is lost, the length of the surgery, and how well patients recover afterwards.

To be eligible for this trial, patients must be between 18 and 70 years old and have certain types of liver diseases, like primary liver cancer or other related conditions. They also need to have a specific level of liver function and must be able to tolerate the surgery. Participants can expect to receive close monitoring throughout the procedure and will help contribute to a new treatment strategy that aims to improve care for patients undergoing liver surgery. This trial is an important step towards enhancing surgical techniques and ensuring better outcomes for liver cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Preoperative Child-Pugh classification of liver function Grade A and grade B;
• • 2. No contraindications for laparoscopic hepatectomy;
• • 3. Liver diseases include: primary liver cancer, hepatic hemangioma, intrahepatic bile duct calculus, intrahepatic bile duct cell carcinoma, etc.
• • 4. Patients voluntarily participate and sign informed consent;
• • 5. According to the Ban difficulty scoring system of laparoscopic hepatectomy, patients with difficulty score of 5 or more were included; Neoplasms near the hepatic portal; Extensive hepatectomy (3 hepatic segments). Patients aged 18-70 years (including 18-70 years)
• Exclusion Criteria:
• • 1. Poor liver reserve function, ICG retention rate \> 15%;
• • 2. severe heart and lung diseases, unable to tolerate general anesthesia surgery;
• • 3. Previous history of liver surgery;
• 4. More than medium amount of chest and abdominal fluid with clinical symptoms:
• • 5. hepatic encephalopathy;
• • 6. having a history of psychotropic drug abuse, unable to quit or having a history of mental disorders;
• • 7. Patients who have received solid organ transplantation or bone marrow transplantation, or within 2 years before surgery
• • 8. An active autoimmune disease requiring systemic treatment has occurred;
• • 9. There is an immune deficiency disease or HIV infection;
• • 10. Those who were not considered suitable for inclusion by the researchers.
• • 11. Progression of the disease or toxic side effects or serious adverse events that the subjects could not tolerate before surgery after treatment;
• • 12. Poor patient compliance, non-cooperation, concealment, false reporting and other phenomena: others
• • 13. Cases where the principal investigator determines that the research protocol is seriously violated.